<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332212</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0148</org_study_id>
    <secondary_id>2017-000376-28</secondary_id>
    <nct_id>NCT03332212</nct_id>
  </id_info>
  <brief_title>A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin</brief_title>
  <official_title>EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the effect of empagliflozin on cardiac physiology&#xD;
      and metabolism aiming to provide a scientific explanation of the underlying mechanism by&#xD;
      which empagliflozin improves HF related outcomes in patients with chronic heart failure&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">May 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).</measure>
    <time_frame>At baseline and at week 12.</time_frame>
    <description>The primary endpoint of efficacy was the change from baseline to Week 12 in phosphocreatine/adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy (MRS).&#xD;
Adjusted mean values were calculated using an analysis of variance (ANOVA) model, with treatment, history of diabetes, and history of atrial fibrillation (AF) as fixed effects.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart Failure with Reduced Ejection Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart Failure with Preserved Ejection Fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>12 weeks</description>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <other_name>JARDIANCE, JARDIANZ, GIBTULIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 Weeks</description>
    <arm_group_label>Cohort A (Empagliflozin + Placebo)</arm_group_label>
    <arm_group_label>Cohort B (Empagliflozin + Placebo)</arm_group_label>
    <other_name>JARDIANCE, JARDIANZ, GIBTULIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic heart failure diagnosed at least 3 months before informed consent&#xD;
&#xD;
          -  NYHA class II-IV at screening&#xD;
&#xD;
          -  Age ≥ 18 years at screening&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP) must be ready and&#xD;
             able to use highly effective methods of birth control per ICH M3 (R2) that result in a&#xD;
             low failure rate of less than 1% per year when used consistently and correctly. A list&#xD;
             of contraception methods meeting these criteria is provided in the patient&#xD;
             information.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial&#xD;
&#xD;
        Cohort A Heart Failure with Reduced Ejection Fraction (HFrEF)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≤ 40% as measured by ECHO at screening&#xD;
&#xD;
          -  The following signs of heart failure;&#xD;
&#xD;
               -  Elevated NT-proBNP (&gt;125 pg/mL) at screening in patient without atrial&#xD;
                  fibrillation (AF)&#xD;
&#xD;
               -  Elevated NT-proBNP (&gt;600 pg/mL) at screening in patient with AF&#xD;
&#xD;
          -  Appropriate dose of medical therapy for HF (such as ACEi, ARB, β-blocker, oral&#xD;
             diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international&#xD;
             HF guidelines, stable for at least one week prior to Visit 1 and during screening&#xD;
             period until Visit 2 (Randomisation) with the exception of diuretics which must be&#xD;
             stable for at least one week prior to Visit 2 to control symptoms. If required, the&#xD;
             investigator must document in the source documents the reason why the patient is not&#xD;
             on the target dose per local guidelines.&#xD;
&#xD;
        Cohort B Heart Failure with Preserved Ejection Fraction (HFpEF)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% as measured by ECHO at screening and&#xD;
             no previous measurement of LVEF ≤ 40%.&#xD;
&#xD;
          -  The following combined signs of heart failure;&#xD;
&#xD;
               -  Structural heart disease (LA enlargement [LAVI &gt;34 mL/m2] and/or LVH [LVMI ≥ 115&#xD;
                  g/m2 for males and ≥ 95 g/m2 for females]) by ECHO at screening or within 3&#xD;
                  months prior to informed consent AND&#xD;
&#xD;
               -  NT-proBNP &gt; 125pg/mL at screening in patient without AF or NT-pro-BNP &gt; 600 pg/mL&#xD;
                  in patient with AF&#xD;
&#xD;
          -  Oral diuretics, if prescribed, should be stable for at least one week prior to Visit 1&#xD;
             and during screening period until Visit 2 (Randomisation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stroke or transient ischaemic attack (TIA) within 6 months prior to informed consent.&#xD;
&#xD;
          -  Any patients with myocardial scars and/or non-viable myocardium in the&#xD;
             interventricular septum, unstable angina due to significant coronary artery disease&#xD;
             (CAD), or major (in the opinion of the investigator) cardiovascular surgery.&#xD;
&#xD;
          -  Any contraindication for MRI, CPET and/or dobutamine stress test in accordance with&#xD;
             the institution guidance, including implanted left ventricular assist device&#xD;
             (LVAD),implantable cardioverter defibrillator (ICD), cardiac resynchronisation therapy&#xD;
             (CRT) or any cardiac device.&#xD;
&#xD;
          -  Heart transplant recipient or listed for heart transplant&#xD;
&#xD;
          -  Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation&#xD;
             diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy&#xD;
             with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive&#xD;
             cardiomyopathy or known pericardial constriction&#xD;
&#xD;
          -  Moderate to severe uncorrected valvular heart disease, obstructive or regurgitant, or&#xD;
             any valvular heart disease expected to lead to surgery in the Investigator's opinion&#xD;
&#xD;
          -  Acute decompensated HF (exacerbation of chronic HF) requiring intravenous (i.v.)&#xD;
             diuretics, i.v. inotropes or i.v. vasodilators, or LVAD or hospitalisation within 1&#xD;
             week prior to Visit 1 (Screening), or during screening period until Visit 2&#xD;
             (Randomisation)&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥ 180 mmHg at screening. If SBP &gt;150 mmHg and &lt;180mmHg&#xD;
             at screening, the patient is ineligible if receiving 3 or more antihypertensive drugs&#xD;
&#xD;
          -  Symptomatic hypotension and/or a SBP &lt; 100 mmHg at Screening&#xD;
&#xD;
          -  Atrial fibrillation which is uncontrolled in the opinion of the investigator&#xD;
&#xD;
          -  Untreated ventricular arrhythmia with syncope documented within the 3 months prior to&#xD;
             informed consent in patients without ICD&#xD;
&#xD;
          -  Diagnosis of cardiomyopathy induced by chemotherapy or peripartum within the 12 months&#xD;
             prior to informed consent&#xD;
&#xD;
          -  Symptomatic bradycardia or second or third degree heart block in need of a pacemaker&#xD;
             after adjusting beta-blocker therapy or any other negative inotropic agents, if&#xD;
             appropriate&#xD;
&#xD;
          -  Chronic pulmonary disease requiring home oxygen, oral steroid therapy or&#xD;
             hospitalisation for exacerbation within 12 months prior to informed consent, or&#xD;
             significant chronic pulmonary disease in the Investigator's opinion, or primary&#xD;
             pulmonary arterial hypertension&#xD;
&#xD;
          -  Indication of liver disease, defined by serum levels of either ALT (SGPT), AST&#xD;
             (SGOT),or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at&#xD;
             screening&#xD;
&#xD;
          -  Impaired renal function, defined as estimated Creatinine Clearance &lt; 30 mL/min (using&#xD;
             Cockcroft-Gault formula) or requiring dialysis, as determined at screening&#xD;
&#xD;
          -  Haemoglobin &lt; 10 g/dL at screening&#xD;
&#xD;
          -  Type 1 Diabetes Mellitus (T1DM)&#xD;
&#xD;
          -  History of ketoacidosis&#xD;
&#xD;
          -  Major surgery (major according to the investigator's assessment) performed within 3&#xD;
             months prior to informed consent, or scheduled major elective surgery (e.g. hip&#xD;
             replacement) within 3 months after Visit 1&#xD;
&#xD;
          -  Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of&#xD;
             trial medication in the investigator's opinion&#xD;
&#xD;
          -  Any documented active or suspected malignancy or history of malignancy within 6 months&#xD;
             prior to informed consent, except appropriately treated basal cell carcinoma of the&#xD;
             skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with&#xD;
             pretreatment PSA &lt;10 ng/mL, and biopsy Gleason score of ≤ 6 and clinical stage T1c or&#xD;
             T2a)&#xD;
&#xD;
          -  Presence of any other disease than heart failure with a life expectancy of &lt;1 year in&#xD;
             the investigator's opinion&#xD;
&#xD;
          -  Patients who must or wish to continue the intake of restricted medications or any drug&#xD;
             considered likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          -  Patients with requirement for treatment with empagliflozin according to local standard&#xD;
             of care&#xD;
&#xD;
          -  Treatment with any SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor within 1 week&#xD;
             prior to informed consent or during screening period until Visit 2 (Randomisation)&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug study, or less than 30&#xD;
             days between randomisation and ending another investigational device or drug study, or&#xD;
             receiving other investigational treatment(s). Patients participating in a purely&#xD;
             observational trial will not be excluded.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes them an unreliable trial subject or unlikely to complete the trial&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or who plan to become pregnant while in the&#xD;
             trial&#xD;
&#xD;
          -  Any clinical condition that would jeopardise patients safety while participating in&#xD;
             this trial, or may prevent the subject from adhering to the trial protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>May 26, 2021</results_first_submitted>
  <results_first_submitted_qc>May 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03332212/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03332212/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A randomised, double-blind, placebo controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with heart failure.</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in trial. Subjects attended specialist site to ensure that they (the subjects) met all implemented inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Cohort A</title>
          <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Cohort B</title>
          <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 10mg Cohort A</title>
          <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 10mg Cohort B</title>
          <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>worsening of disease under study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomised set (RS): This set included all patients who were randomised to study treatment, in line with the intention-to-treat principle.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Cohort A</title>
          <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Cohort B</title>
          <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 10mg Cohort A</title>
          <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
        </group>
        <group group_id="B4">
          <title>Empagliflozin 10mg Cohort B</title>
          <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="12.7"/>
                    <measurement group_id="B2" value="72.1" spread="7.0"/>
                    <measurement group_id="B3" value="67.5" spread="14.1"/>
                    <measurement group_id="B4" value="69.1" spread="10.9"/>
                    <measurement group_id="B5" value="68.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ratio of phosphocreatine to adenosine triphosphate concentration</title>
          <description>The ratio of phosphocreatine to adenosine triphosphate concentration (PCr/ATP) reflects the energetic state of the heart and was assessed by 31P cardiac magnetic resonance spectroscopy (MRS).</description>
          <population>In the Placebo arm (Cohort B) there was one patient without baseline Cardiac magnetic resonance (CMR) measures.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="18"/>
                    <count group_id="B5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.924" spread="0.354"/>
                    <measurement group_id="B2" value="1.719" spread="0.431"/>
                    <measurement group_id="B3" value="1.889" spread="0.407"/>
                    <measurement group_id="B4" value="1.896" spread="0.462"/>
                    <measurement group_id="B5" value="1.859" spread="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).</title>
        <description>The primary endpoint of efficacy was the change from baseline to Week 12 in phosphocreatine/adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy (MRS).&#xD;
Adjusted mean values were calculated using an analysis of variance (ANOVA) model, with treatment, history of diabetes, and history of atrial fibrillation (AF) as fixed effects.</description>
        <time_frame>At baseline and at week 12.</time_frame>
        <population>Per protocol set (PPS):&#xD;
The primary endpoint analysis was performed using the per protocol (PP) set of patients with valid PCr/ATP ratio measurements available at baseline and Week 12, and no important protocol violation relevant to the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cohort B</title>
            <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10mg Cohort A</title>
            <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF).</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10mg Cohort B</title>
            <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks.&#xD;
Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).</title>
          <description>The primary endpoint of efficacy was the change from baseline to Week 12 in phosphocreatine/adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy (MRS).&#xD;
Adjusted mean values were calculated using an analysis of variance (ANOVA) model, with treatment, history of diabetes, and history of atrial fibrillation (AF) as fixed effects.</description>
          <population>Per protocol set (PPS):&#xD;
The primary endpoint analysis was performed using the per protocol (PP) set of patients with valid PCr/ATP ratio measurements available at baseline and Week 12, and no important protocol violation relevant to the primary endpoint.</population>
          <units>PCr / ATP Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.114"/>
                    <measurement group_id="O2" value="0.259" spread="0.156"/>
                    <measurement group_id="O3" value="-0.179" spread="0.117"/>
                    <measurement group_id="O4" value="0.100" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA on the PCr/ATP ratio absolute change using treatment (empagliflozin vs. placebo), history of diabetes (yes vs, no) and history of atrial fibrillation (yes vs no) as between subjects factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1418</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.247</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.164</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.582</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA on the PCr/ATP ratio absolute change using treatment (empagliflozin vs. placebo), history of diabetes (yes vs, no) and history of atrial fibrillation (yes vs no) as between subjects factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4650</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.213</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.604</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring between the start of treatment and end of the residual effect period, 7 days after the last dose of medication. Up to 95 days.</time_frame>
      <desc>Treated set (TS): All randomised and treated patients were included in the safety analysis and safety summaries were presented by actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Once a day oral administration of a single film-coated placebo tablet matching to empagliflozin for 12 weeks. Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF) and Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10mg</title>
          <description>Once a day oral administration of a single 10 milligram (mg) film-coated empagliflozin tablet for 12 weeks. Cohort A: Heart failure (HF) with reduced ejection fraction (HFrEF) and Cohort B: Heart failure (HF) with preserved ejection fraction (HFpEF).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Euglycaemic diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the suspension of face-to-face contact imposed in March 2020 to restrict transmission of COVID-19, the number of patients included in the analysis of efficacy for the Heart failure with preserved ejection fraction was substantially reduced, which meant that this cohort was also under powered (reduced from 80% to 70%) for the planned analysis of the primary endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim , Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

